Skip to main content
. 2018 Jan 17;92(3):e01717-17. doi: 10.1128/JVI.01717-17

FIG 4.

FIG 4

SVA VP-specific antibody responses after resolution of clinical disease. Anti-SVA VP1, VP2, and VP3 IgM (A) and IgG (B) responses assessed by FMIA on days 0, 14, and 35 p.i. are shown. P values were determined by Sidak's multiple-comparison test. *, P < 0.05; **, P < 0.01; ***, P < 0.001.